Metropolis Healthcare shares jump over 4% on robust Q3 business updates

Metropolis Healthcare's share price jumps over 4% after the company announced robust Q3 business updates. The shares traded 4.17% higher at ₹2,013 apiece on the NSE at 11:00 am. The shares have delivered a muted performance of -7% in 2025 in tandem with the broader market performance.

The shares were in focus in Monday’s trade after the company announced a 26% YoY jump in revenue for the quarter ending December 31. The exchange filing read, The company delivered a strong 26% year-on-year consolidated revenue growth, driven by sustained momentum in preventive and wellness health check-ups under TruHealth, along with a strong increase in specialty testing volumes across both B2C and B2B channels.

Supported by an expanded Core Diagnostics test menu for high-end speciality testing and continuous in-house innovation, the company has successfully scaled its speciality business across its pan-India network.

Among other key highlights, the company’s Q3 update includes the integration of all acquisitions. The synergies delivered operational efficiencies and strengthened operating leverage, supported by continued growth in revenues and profitability. Core Diagnostics' margins are trending in line with our estimates and remain similar to Q2 levels. DAPIC (Dehradun), Scientific (Agra), and Ambika (Kolhapur) continue to outperform the Company’s average margins.

The TruHealth Wellness and Speciality segments recorded 35% and 33% YoY growth, respectively, for Q3FY26. Similarly, for B2B revenue growth was seen at ₹18% YoY. On a Standalone basis, the revenue jumped 15% YoY, primarily led by increased patient count and a favourable shift in product mix. The EBITDA margins also recorded expansion, despite being a seasonally weak quarter.